Pharming Group (PHARM) investor relations material

Executive summary

• Q3 2026 revenue was approximately $117.6 million, up 21% YoY, driven by RUCONEST and Joenja; operating expenses were approximately $74.6 million.

• 2026 revenue guidance narrowed to $380 million–$390 million, while operating expense guidance was lowered to $310 million–$315 million.

Financial highlights

• Q3 total revenue was approximately $117.6 million versus $97.3 million in Q3 2025, an increase of 21% YoY.

• Q3 total operating expenses were approximately $74.6 million versus $74.5 million in Q3 2025, reflecting efficient scaling.

Outlook and guidance

• FY 2026 revenue guidance tightened to $380 million–$390 million, implying 1%–4% growth, from $375 million–$395 million and 0%–5% growth.

• FY 2026 operating expense guidance lowered to $310 million–$315 million, implying 0%–1% growth, from $315 million–$320 million and 1%–3% growth.

• Topline Phase II results for leniolisib in CVID patients with immune dysregulation are expected in November 2026; a broader registrational Phase III trial is planned.

• Napazimone FALCON enrollment is expected to reach ~145 of 180 subjects by end-2026 and finish in H1 2027; topline results are expected ~one year after enrollment completes.